Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

After 12 weeks of treatment, participants deriving clinical benefit were offered enrollment in a separate long-term extension study (ACH471-103, NCT03181633).

Inclusion criteria

• Currently untreated PNH participants with PNH Type III erythrocyte and/or granulocyte clone size ≥10% and anemia (hemoglobin <12 grams/deciliter) with adequate reticulocytosis (as determined by the Investigator).
• LDH ≥1.5 x the upper limit of normal.
• Platelets ≥50,000/microliter without the need for platelet transfusions.
• Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae, or willingness to receive vaccinations during the screening period.
• Negative pregnancy test for females prior to dosing and throughout the study.

Exclusion criteria

• History of a major organ transplant (for example, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
• Participants who had received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater.
• Participants who had received eculizumab at any dose or interval within the past 75 days before study entry.
• Participants with known or suspected complement deficiency.
• Participants with active bacterial infection or clinically significant active viral infection, a body temperature >38°Celsius, or other evidence of infection on Day 1, or with a history of febrile illness within 14 days prior to first study drug administration.
• History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection.
• Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or participants with a female partner who was pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration.